Shots:
- The P-III STAR study involves assessing the safety and efficacy of a single subretinal injection of timrepigene emparvovec (BIIB111/AAV2-REP1) in 169 adult males with a genetically confirmed diagnosis of choroideremia
- The study did not meet its 1EPs i.e. improvement of at least 15 letters from baseline in BCVA @12mos. post-treatment as measured by the ETDRS chart. The study also failed to meet its 2EPs, safety results were consistent with previous studies
- Biogen will evaluate the complete data set before confirming the next steps for the timrepigene emparvovec clinical program
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Stat News
The post Biogen’s BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia first appeared on PharmaShots.
